- Respiratory Immunology and Inflammation (pathogenesis)
- Dendritic cells
- Regulatory T cells
- Th2 cells
Dr. Gordon obtained his PhD from the University of Saskatchewan (1984), did fellowships at the National Institute for Medical Research at Mill Hill, UK (1984-87) and the Department of Pathology at Harvard Medical School (1987-91) in allergy/mast cell biology.
He joined the University of Saskatchewan in 1991 as an Associate Professor. He has served as the Associate Dean Research (Acting) for the College of Medicine and is presently a Professor in the Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, while also seconded as a Special Advisor (Clinical Research) to the Office of the Vice-President Research, Univ Sask.
The central focus of Dr. Gordon’s lab is the development of immunotherapeutics for allergic and other inflammatory diseases. They developed, patented and licensed out a novel therapeutic that is highly effective in models of inflammatory diseases in multiple species, and is presently being developed as an adjunct therapy for cancers.
Their lab has also been investigating regulatory dendritic cell (DCreg) therapies for allergic and immunologic diseases, having shown that these cells can reverse asthma and food allergies in mouse models, and that this same approach works to suppress immune cells from allergic donors. His lab has published over 130 research articles that have been referenced some 10,000 times, such that they have been recognized with numerous research awards.
Dr. Gordon has served as a member of numerous Medical-Scientific Advisory Boards (e.g., CIHR Institute for infection and Immunity Institute Advisory Board, Gairdner Canada Foundation), Boards of Directors or Executive Committees for national or international Societies, and been elected to Fellowship in the Canadian Academy of Health Sciences. He is a past-President of the Canadian Society for Immunology
- Asthma & allergic inflammation
- Neutrophilic inflammation
- Lung Immunology
h-index (Google Scholar)
Total Citations (Google Scholar)
i10 Index (papers cited more than 10 times) (Google Scholar)
- Z.E. Gillespie, K. MacKay, M. Sander, B. Trost, W. Dawicki, A. Wickramarathna, J.R. Gordon, I. Kill, J. Bridger, A. Kusalik, J.A. Mitchell, C.H Eskiw. 2016. Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production. Nucleus 6:490-506
- B.J. Connell1, J.R. Gordon, T.M. Saleh. 2015. ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke. Neurosci Lett 606:117-22
- M. Asaduzzaman, A. Nadeem, N. Arizmendi, C. Davidson, H. Nichols, M. Abel, L. Ionescu, L. Puttagunda, B. Thebaud, J.R. Gordon, K. Defea, M. Hollenberg, & H. Vliagoftis. 2015. Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. Clin Exp Allergy 45:1844-55
- M. Khan, B. Wang, J. Wei, Y Zhang, Q. Li, X. Luan, J-W. Cheng, J.R. Gordon, F. Li, and H. Liu. 2015. CXCR1/2 antagonism with a CXCL8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumour cell proliferation and suppressing angiogenesis. Oncotarget 6:21315-27
- L. Li, M.N. Khan, Q. Li, X. Chen, J. Wei, B. Wang, J.W. Cheng, J.R. Gordon, F. Li. 2015. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity. Oncol Rep 33:751-7
- D. Schneberger, J.R. Gordon, A.J. Heires, J.D.DeVasure, J.A. Boten, D.J. Romberger, T.A. Wyatt. 2015. CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice. Pulm Pharmacol Therap 31:55-62
- S.A. Ballendine, Q. Greba, W. Dawicki, X. Zhang, J.R. Gordon, J.G. Howland. 2015. Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders. Prog Neuro-psychopharm Biol Psych 57:155-65
- P. Novakovic, Y.Y. Huang, B. Lockerbie, F. Shahriar, J. Kelly, J.R. Gordon, D.M. Middleton, M.E. Loewen, B.A. Kidney, and E. Simko. 2015. Identification of F4ac-binding proteins of porcine milk fat globule membranes. Canadian Journal of Veterinary Research 79:120-8
- J.R. Gordon, Y. Ma, L. Churchman, S.A. Gordon and W. Dawicki. 2014. Regulatory dendritic cells for immunotherapy in immunologic diseases. Frontiers in Immunology 5: 7 (12 pp; doi: 10.3389/fimmu.2014.00007) (Invited Review)
- J. Wei, X Chen, Q Li, J Chen, N Khan, B. Wang, J-W Cheng, JR Gordon and F Li. ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity. 2014. Oncol. Reports 31:1599-604
Patents (last 5 yr; total, 13)
- Uses of modified ELR-CXC chemokine G31P to treat cancer. JR Gordon, F Li. 2012, WO Patent 2,012,122,642
- High-affinity antagonists of ELR-CXC chemokines. JR Gordon. 2011, EP Patent 2,021,475
- Method of treatment using high-affinity antagonists of ELR-CXC chemokines. JR Gordon. 2011, US Patent 8,039,429
- Uses of Modified ELR-CXC Chemokine G31P To Treat Cancer. JR Gordon, F Li. 2011, US Patent App. 13/048,290
- Uses of modified ELR-CXC chemokine G31P. JR Gordon. 2010, EP Patent 2,257,303
- High-affinity antagonists of ELR-CXC chemokines. JR Gordon, F Li. 2010, US Patent 7,741,434
Principle Investigator (recent)
- AllerGen National Centre for Excellence. Development of human dendritic cell immunotherapy for treatment of asthma and allergy. 2015-19. $210,000
- Saskatchewan Health Research Foundation (SHRF) Collaborative Innovation grant. Cellular immunotherapy for atopic dermatitis and the 'atopic march' to asthma. Co-applicants: D. Lichtenwald, E. Simko & C. Rudulier. 2016-17. $40,000
- SHRF Collaborative Innovation grant. Optimizing regulatory dendritic cell immunotherapy for asthma. Co-applicants: D. Cockcroft, S. Van den Hurk. 2015-16. $40,000
- NSERC Discovery grant. ELR-CXC chemokines in tumour progression. $165,000. 2014-19.
- CIHR Operating grant. Regulatory dendritic cell immunotherapy for allergic diseases. 2013-18. $660,000.
- AllerGen CIHR National Centre of Excellence. Preventing Severe Reactions - Preclinical Studies. 2012-16. $235,510
- SHRF Research Groups (Phase II) operating grant. Airways Research Group (Project: Impact of air quality on the respiratory health in rural Saskatchewan). 2011-2014. $360,000 (with matching funds from the UofS)
Co-applicant: Last 4 years
- T. Harkness, T. Arnason, JR Gordon & G. Groot. SHRF Collaborative Innovation grant. In vivo and in vitro evaluation of patient-derived breast cancer cells for early detection and treatment of drug-resistant tumors. 2015-16. $40,000
- B. Mazer, A. Clarke, J. Marshall, Y. Asai, M. Ben-Shoshan, S. Elliott, C. Piccirillo, A Sanford. GET-FACTS: Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies. CIHR Programmatic Grants in Food and Health. 2013-18. $1.5M
- B. Singh, V. Gerdts, & J.R. Gordon. Integrated Training Program (ITraP) for Infectious Diseases & Food Safety. NSERC CREATE program. 2011-2016. $4.6M (with matching funds)
- S. Fowler, J. Jones, P. Hull and J.R. Gordon. The immunological effects of extracorporeal photopheresis in Crohn’s Disease. Royal University Hospital Foundation. 2012-13. $20,000
- M. Fenton & J.R. Gordon. Induction of transplant tolerance using IL-10-differentiated regulatory dendritic cells. Canadian Lung Association. 2012-14. $60,000
- B. Singh, D. Freeman, L. Martz, R. Buckingham, J.R. Gordon. International Partnership Fund Program matching grant (Univ Saskatchewan/Guru Angad Dev Veterinary & Animal Sciences Univ, Ludhiana, India). Partnership engagement infrastructure grant. 2010-13. $300,000
- M. Fenton (& 6 co-applicants). CIHR MPD (meetings) grant. Planning workshop for spirometric evaluation of Canadian First Nations to establish normative values. 2010-11. $9,970
- J. Dosman, S. Abonyi, J. Episkenew, P. Pahwa (and 12 co-applicants). CIHR Operating Grant. Assess, Redress, Re-assess: Addressing Disparities in Respiratory Health among First Nations People. 2011-16. $1.98M.